Daymond John's Investments Need to "Resonate" With Him
Shark Tank's Daymond John visits the NYSE for the 94th annual tree lighting. He stops by Cheddar to discuss his favorite deals from the year and the best business advice he's ever received.
John says that when an entrepreneur pitches on Shark Tank, he looks for someone who would work on their idea and company without being paid. He values passion and determination and uses that as an indicator of success.
"They tell us about all the mistakes they made, they have a passion about it," he tells Cheddar. "I feel like the train is gonna leave whether I'm on it or not. They know their customer very well, so they're not using my money as tuition....and I have to like the person."
John looked back on some of his Shark Tank deals. He explains his decision behind his deal with Moziah Bridges of Mo's Bows. Initially, Moziah pitched the Sharks on $50,000 in exchange for 20%. John came back and told him not to take any money, and instead to accept his offer of mentorship.
John explained to Cheddar that he received a similar offer when he was starting his clothing company, FUBU, and it proved to be incredibly helpful and lucrative.
A winter storm dumped heavy, wet snow in parts of the Northeast on Tuesday, causing tens of thousands of power outages, widespread school closings, dangerous road conditions and a plane to slide off a taxiway.
Silicon Valley Bank’s collapse rattled the technology industry that had been the bank's backbone, leaving shell-shocked entrepreneurs thankful for the government reprieve that saved their money while they mourned the loss of a place that served as a chummy club of innovation.
Roku was among those businesses impacted by the fall of Silicon Valley Bank, having around 26 percent of its cash and cash equivalents deposited at the bank.
Depositors withdrew savings, and investors broadly sold off bank shares as the federal government raced to reassure Americans that the banking system is secure following two bank failures.
Pfizer has entered a $43 billion merger agreement with biotechnology firm Seagen in a deal designed to bolster the pharmaceutical giant's efforts to fight cancer
